Navigation Links
Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
Date:3/17/2009

Cardio-diagnostic company adds new apoAI measurement and apoB/apoAI ratio to advanced lipid profile for heart disease risk stratification

BIRMINGHAM, Ala., March 17 /PRNewswire/ -- Atherotech, Inc., today announced it will be exhibiting its VAP(R) Cholesterol Test in booth #1263 at ACC.09, the American College of Cardiology (ACC) 58th Annual Scientific Session Exposition. The annual meeting takes place March 29-31, 2009, at the Orange County Convention Center in Orlando, Fla.

Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention (HAPI) Heart Study recently published in Science, the VAP (Vertical Auto Profile) Test is the most accurate cholesterol test available today.

The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

Atherotech recently announced the addition of apolipoprotein AI (apoAI), the main component of protective HDL cholesterol, to its reporting. Several large, prospective studies, including INTERHEART and the AMORIS trials, have clearly shown the apoB/apoAI ratio to be superior to all other cardiovascular disease risk marker ratios.

"ACC 2009 represents an excellent setting in which to convey the unique benefits of advanced cholesterol profiling to medical professionals from around the world," said Atherotech Chief Medical Officer James Ehrlich, M.D.

Atherotech representatives will be available to discuss the VAP Cholesterol Test in booth #1263, and blood draws will be provided to qualified attendees during exhibit hours March 29-31. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.

The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with triglycerides > 150, HDL < 40, LDL >130, total cholesterol > 200) should also opt for the more detailed VAP Test.

The VAP Test is available nationwide and is covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
2. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
3. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
4. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
5. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
6. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
7. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
8. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
9. Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference
10. Cadient Groups GEL Interactive Technologies to Launch Immerse(SM) Exhibit 4.0 at EXHIBITOR2009
11. National Ergonomics Conference and Expo Reaches 94% Exhibitor Renewal Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):